Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.
Vu H DuongAmy S RuppertAlice S MimsUma BorateEytan M SteinMaria R BaerWendy StockTibor KovacsovicsWilliam G BlumMartha L ArellanoGary J SchillerRebecca L OlinJames M ForanMark R LitzowTara L LinPrapti A PatelMatthew C FosterRobert L RednerZeina Al-MansourChristopher R CogleRonan T SwordsRobert H CollinsJo-Anne VergilioNyla A HeeremaLeonard RosenbergAshley O YocumSonja MarcusTimothy ChenFranchesca DrugganMona StefanosTheophilus J GanaAbigail B ShobenBrian J DrukerAmy BurdJohn C ByrdRoss L LevineMichael M BoyiadzisPublished in: Cancer (2023)
The combination of entospletinib and decitabine demonstrated activity and was acceptably tolerated in this patient population; however, the CR rates were low, and overall survival was short. Novel treatment strategies for older patients with TP53 mutations and complex karyotype remain an urgent need.